CA2836353A1 - Use of sigma ligands in diabetes type-2 associated pain - Google Patents

Use of sigma ligands in diabetes type-2 associated pain Download PDF

Info

Publication number
CA2836353A1
CA2836353A1 CA2836353A CA2836353A CA2836353A1 CA 2836353 A1 CA2836353 A1 CA 2836353A1 CA 2836353 A CA2836353 A CA 2836353A CA 2836353 A CA2836353 A CA 2836353A CA 2836353 A1 CA2836353 A1 CA 2836353A1
Authority
CA
Canada
Prior art keywords
pyrazol
dichlorophenyl
yloxy
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2836353A
Other languages
English (en)
French (fr)
Inventor
Jose Miguel Vela Hernandez
Maria Isabel Martin Fontelles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of CA2836353A1 publication Critical patent/CA2836353A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2836353A 2011-05-19 2012-05-18 Use of sigma ligands in diabetes type-2 associated pain Abandoned CA2836353A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382157.3 2011-05-19
EP11382157A EP2524694A1 (en) 2011-05-19 2011-05-19 Use of sigma ligands in diabetes type-2 associated pain
PCT/EP2012/059232 WO2012156497A1 (en) 2011-05-19 2012-05-18 Use of sigma ligands in diabetes type-2 associated pain

Publications (1)

Publication Number Publication Date
CA2836353A1 true CA2836353A1 (en) 2012-11-22

Family

ID=44712933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2836353A Abandoned CA2836353A1 (en) 2011-05-19 2012-05-18 Use of sigma ligands in diabetes type-2 associated pain

Country Status (21)

Country Link
US (1) US9789117B2 (ru)
EP (2) EP2524694A1 (ru)
JP (1) JP6029190B2 (ru)
KR (1) KR101937255B1 (ru)
CN (1) CN103547264B (ru)
AR (1) AR086636A1 (ru)
AU (1) AU2012258219B2 (ru)
BR (1) BR112013029609A2 (ru)
CA (1) CA2836353A1 (ru)
CO (1) CO6831985A2 (ru)
IL (1) IL229495B (ru)
MA (1) MA35401B1 (ru)
MX (1) MX343437B (ru)
MY (1) MY169731A (ru)
RU (1) RU2608943C2 (ru)
SG (1) SG194924A1 (ru)
TN (1) TN2013000460A1 (ru)
TW (1) TWI582079B (ru)
UA (1) UA113849C2 (ru)
WO (1) WO2012156497A1 (ru)
ZA (1) ZA201308926B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) * 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
CA2922330A1 (en) * 2013-09-12 2015-03-19 Laboratorios Del Dr. Esteve, S.A. Nsaid and sigma receptor ligand combinations
EP3082790A1 (en) * 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
JP2016540771A (ja) 2013-12-17 2016-12-28 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ セロトニン−ノルアドレナリン再取り込み阻害薬（ｓｎｒｉ）およびシグマ受容体リガンドの組み合わせ
ES2700448R1 (es) * 2016-06-07 2019-02-26 Esteve Pharmaceuticals Sa Uso de ligandos del receptor sigma en la diabetes y el sindrome metabolico
AR109024A1 (es) * 2016-07-12 2018-10-17 Esteve Labor Dr Uso de ligandos del receptor sigma en el dolor post-herpético
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
US2908677A (en) 1955-03-30 1959-10-13 Eastman Kodak Co Nickel and cobalt complexes of pyrazolone monoazo compounds
US3428634A (en) 1965-03-13 1969-02-18 Acraf 3-tertiary amino alkoxy-1-hydrocarbon indazoles
CH471199A (de) 1965-07-06 1969-04-15 Sandoz Ag Verfahren zur Herstellung metallhaltiger Azofarbstoffe
DE2313722C3 (de) 1973-03-20 1987-04-16 Bayer Ag, 5090 Leverkusen Chromischkomplex-Farbstoff und dessen Verwendung zum Färben und Bedrucken von stickstoffhaltigen Fasermaterialien
IT1005472B (it) 1974-02-15 1976-08-20 Montedison Spa Procedimento per la preparazione del 2,5, dimetil 3,2h, furanone
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2301250A1 (fr) 1975-02-21 1976-09-17 Bellon Labor Sa Roger Nouveaux diaryl-1, 4o-aminoalcoxy-3 pyrazoles et leurs sels
CA1121651A (en) 1978-07-27 1982-04-13 Chi-Kuen Shu 2,5-dialkyl dihydrofuranones and 2,4,5-trialkyl dihydrofuranones, mixtures of same and organoleptic uses thereof
US4207392A (en) 1978-10-30 1980-06-10 Eastman Kodak Company Heat developable and stabilizable photographic materials and process
FR2460299A1 (fr) 1979-07-05 1981-01-23 Bellon Labor Sa Roger Nouveaux derives du pyrazole et leur application therapeutique
US4234616A (en) 1979-08-03 1980-11-18 International Flavors & Fragrances Inc. Flavoring with mixtures of 2,5-dialkyl dihydrofuranones and 2,4,5-trialkyl dihydrofuranones
FR2472564A1 (fr) 1979-12-31 1981-07-03 Bellon Labor Sa Roger Nouveaux aryl-1 arylsulfonyl-4 1h-pyrazolols-3, et procede pour les preparer
US4826868A (en) 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
GB8917069D0 (en) 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JPH03232817A (ja) 1990-02-07 1991-10-16 Showa Yakuhin Kako Kk 貼付剤
EP0445974A3 (en) 1990-03-05 1992-04-29 Merck Sharp & Dohme Ltd. Spirocyclic antipsychotic agents
JPH04364129A (ja) 1990-10-26 1992-12-16 Asahi Chem Ind Co Ltd ６−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
US5240925A (en) 1991-08-26 1993-08-31 Rohm And Haas Company Fungicidal 2-aryl-2-cyano-2-(heterocyclylalkyl)ethyl-1,2,4-triazoles
RU94046105A (ru) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
JPH1036259A (ja) 1996-04-11 1998-02-10 Kikkoman Corp 白内障の予防または治療薬剤
JPH1055048A (ja) 1996-08-08 1998-02-24 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
WO1998031227A1 (en) 1997-01-21 1998-07-23 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
ES2201482T3 (es) 1997-04-14 2004-03-16 Ufc Limited Derivados de la morfina.
TR199903299T2 (xx) 1997-07-02 2000-07-21 Merck & Co., Inc. Ta�ikinin resept�r antagonisti 2-(R)-(1-(R)- (3,5-Bis(triflorometil) Fenil)Etoksi-3-(S)- (4-Floro)Fenil-4- (3-5(-okso-1H,4H-1,2,4-Triazolo) metilmorfolin'in polimorfik formu.
BR9813284B1 (pt) 1997-10-27 2012-08-21 aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica.
CN1210268C (zh) 1997-12-16 2005-07-13 沃尼尔·朗伯公司 ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CA2304974C (en) 1997-12-16 2005-10-25 Warner-Lambert Company 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
US6545022B1 (en) 1997-12-16 2003-04-08 Pfizer Inc. 4(3)substituted-4(3)-aminomethyl-(thio)pyran or piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO1999059409A1 (en) 1998-05-21 1999-11-25 Matsumoto Rae R Compounds and uses thereof
CA2322558C (en) 1998-05-26 2006-04-11 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
US6166072A (en) 1998-08-03 2000-12-26 Allelix Neuroscience, Inc. Amino acid derivatives
AU9553898A (en) 1998-10-01 2000-04-26 Egis Gyogyszergyar Rt. Pharmaceutical compositions containing an opiate analgesic and a synergizing substance
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE69934902T2 (de) 1998-11-09 2007-10-18 Santen Pharmaceutical Co., Ltd Medikament gegen drogenabhängigkeit
WO2000031020A1 (en) 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
EP1180094B1 (en) 1999-05-26 2004-07-28 Warner-Lambert Company Fused polycyclic amino acids as pharmaceutical agents
BR0011039A (pt) 1999-05-28 2002-02-26 Warner Lambert Co Análogos de gaba substituìdos com 3-heteroarilalquila
DE60000833T2 (de) 1999-06-02 2003-09-18 Warner-Lambert Co., Morris Plains Amino-heterocyclen zur verwendung als pharmazeutische mittel
US7091257B2 (en) 1999-07-27 2006-08-15 Alcatel Radiation-curable composition with simultaneous color formation during cure
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
WO2001064670A1 (fr) 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Nouveaux derives amide cycliques
EP1272567A2 (en) 2000-04-03 2003-01-08 Sun Chemical Corporation Mono- and bis-hydrazone pigments
BR0208922A (pt) 2001-04-19 2004-04-20 Warner Lambert Co Aminoácidos bicìclicos ou tricìclicos fundidos
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
WO2002102387A1 (en) 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
RU2218187C2 (ru) 2002-02-11 2003-12-10 Ростовский научно-исследовательский онкологический институт Способ лечения болевого синдрома у онкологических больных
GB0206505D0 (en) 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
TW200413351A (en) 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
ATE469143T1 (de) 2002-11-15 2010-06-15 Du Pont Neue insektizide vom anthranilamid-typ
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050020483A1 (en) 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
WO2005061462A2 (en) 2003-12-19 2005-07-07 Neurogen Corporation Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators
JP2008507489A (ja) 2004-07-24 2008-03-13 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 機械誘発性異痛に対する治療用のシグマ受容体に活性な化合物の使用
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
SI1781618T1 (sl) * 2004-08-27 2013-01-31 Laboratorios Del Dr. Esteve, S.A. Inhibitorji sigma receptorja
AU2005276591B2 (en) 2004-08-27 2011-03-31 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1634872A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
JP5139061B2 (ja) 2004-08-27 2013-02-06 ラボラトリオス デル ドクトール エステベ エセ．ア． シグマ受容体阻害剤
ES2251316B1 (es) 2004-10-14 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Inhibidores del receptor sigma.
EP1632227A1 (en) 2004-09-07 2006-03-08 Laboratorios del Dr. Esteve S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction
US20080161604A1 (en) * 2005-04-26 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
JP2008179541A (ja) 2005-05-02 2008-08-07 Mochida Pharmaceut Co Ltd 神経因性疼痛治療薬
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
WO2007025613A2 (en) 2005-07-15 2007-03-08 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US20070208134A1 (en) 2005-10-03 2007-09-06 Hunter William L Anti-scarring drug combinations and use thereof
US7872006B2 (en) 2005-10-21 2011-01-18 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
US20090181976A1 (en) 2006-02-28 2009-07-16 Buschmann Helmut H Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome
US8202872B2 (en) 2006-03-01 2012-06-19 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1829875A1 (en) 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1829866A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1829873A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrrazole derivatives as sigma receptors antagonists
JP5017256B2 (ja) 2006-03-22 2012-09-05 パナソニック株式会社 血液検査装置
CN103271920A (zh) 2006-03-27 2013-09-04 威克斯医药有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
EA200802412A1 (ru) * 2006-06-08 2009-06-30 Шварц Фарма Аг Терапевтические комбинации для сопровождающихся болью медицинских состояний
RU2322977C1 (ru) 2006-08-01 2008-04-27 Закрытое акционерное общество "Физиофарм" Синтетическое анальгетическое средство и способ лечения на основе этого средства
EP2066648B1 (en) 2006-08-04 2017-04-12 Laboratorios Del. Dr. Esteve, S.A. Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
EP1921071A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3- triazole derivatives as sigma receptor inhibitors
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
KR100868353B1 (ko) 2007-03-08 2008-11-12 한국화학연구원 도파민 ｄ4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
GB0710981D0 (en) 2007-06-07 2007-07-18 Acacia Pharma Ltd New Therapeutic use
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
EP2090311A1 (en) 2008-02-18 2009-08-19 Laboratorios Del. Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
HUE036546T2 (hu) 2008-02-18 2018-07-30 Esteve Labor Dr Szigma-receptor ligandumokhoz kötõdõ vegyületek alkalmazása kemoterápia következményeként kifejlõdõ neuropátiás fájdalom kezelésére
EP2112139A1 (en) 2008-04-25 2009-10-28 Laboratorios Del. Dr. Esteve, S.A. Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
RU2382646C1 (ru) 2008-11-20 2010-02-27 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи" Способ профилактики и лечения послеоперационного болевого синдрома при обширных торакоабдоминальных операциях
US8192885B2 (en) * 2009-01-26 2012-06-05 GM Global Technology Operations LLC Shutdown strategy for enhanced water management
EP2292236A1 (en) 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2361904A1 (en) 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
RS55099B1 (sr) 2009-11-25 2016-12-30 Esteve Labor Dr Hirohloridna so 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oksi]etil]morfolina
EP2335688A1 (en) 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
PT2531177T (pt) 2010-02-04 2016-08-17 Esteve Labor Dr Polimorfos e solvatos de cloridrato de 4-[-2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2426112A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US20110269727A1 (en) 2010-04-29 2011-11-03 Toledano Annette C Composition to reduce allodynic back pain and related method of use
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460804A1 (en) 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
EP2460519A1 (en) 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
CA2922330A1 (en) 2013-09-12 2015-03-19 Laboratorios Del Dr. Esteve, S.A. Nsaid and sigma receptor ligand combinations
EP3082790A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
JP2016540771A (ja) 2013-12-17 2016-12-28 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ セロトニン−ノルアドレナリン再取り込み阻害薬（ｓｎｒｉ）およびシグマ受容体リガンドの組み合わせ

Also Published As

Publication number Publication date
ZA201308926B (en) 2015-02-25
NZ617590A (en) 2015-05-29
EP2524694A1 (en) 2012-11-21
MA35401B1 (fr) 2014-09-01
AU2012258219A1 (en) 2013-11-28
IL229495A0 (en) 2014-01-30
BR112013029609A2 (pt) 2020-08-25
KR20140033442A (ko) 2014-03-18
EP2709620A1 (en) 2014-03-26
MY169731A (en) 2019-05-14
CO6831985A2 (es) 2014-01-10
UA113849C2 (xx) 2017-03-27
AR086636A1 (es) 2014-01-15
JP6029190B2 (ja) 2016-11-24
CN103547264B (zh) 2017-06-09
US9789117B2 (en) 2017-10-17
RU2013156367A (ru) 2015-06-27
IL229495B (en) 2018-02-28
AU2012258219B2 (en) 2017-01-19
MX2013013479A (es) 2014-08-21
WO2012156497A1 (en) 2012-11-22
MX343437B (es) 2016-11-04
SG194924A1 (en) 2013-12-30
KR101937255B1 (ko) 2019-01-11
US20140107111A1 (en) 2014-04-17
TN2013000460A1 (en) 2015-03-30
JP2014518869A (ja) 2014-08-07
RU2608943C2 (ru) 2017-01-26
TW201300365A (zh) 2013-01-01
CN103547264A (zh) 2014-01-29
TWI582079B (zh) 2017-05-11

Similar Documents

Publication Publication Date Title
AU2012258219B2 (en) Use of sigma ligands in diabetes type-2 associated pain
DK2531191T3 (en) Sigma ligands for use in the prevention and / or treatment of post-operative pain
KR101855357B1 (ko) 오피오이드 유도성 통각과민에서의 시그마 리간드의 용도
TWI629984B (zh) σ配體在與間質性膀胱炎／膀胱疼痛綜合徵（ＩＣ／ＢＰＳ）相關的疼痛的預防和治療中的應用
CN105873580B (zh) 加巴喷丁类化合物与σ受体配体的组合物
AU2014364647A1 (en) Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
KR20170096130A (ko) 골관절염에서 시그마 수용체 리간드의 용도
NZ617590B2 (en) Use of sigma ligands in diabetes type-2 associated pain
WO2014155184A1 (en) Treatment for parkinson's disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170518

FZDE Discontinued

Effective date: 20200831